EUVIMEDEUVIMED entdecken
Systematische Übersicht

Cannabinoids in Treating Parkinson's Disease Symptoms: A Systematic Review of Clinical Studies

Karan Varshney iD, Akash Patel, Siraaj Ansari, Pavan Shet, Sohan Singh Panag

Cannabis & Cannabinoid Research · 01.10.2023 · 8 (5) · 716-730

DOI: 10.1089/can.2023.0023 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cannabis & Cannabinoid Research, online erschienen am 09.10.2023. Verfasst von Karan Varshney und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Deakin University, Waurn Ponds, Victoria, Australia. Hauptthemen laut MEDLINE: Cannabinoids, Parkinson Disease, Cannabidiol, Cannabis. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Parkinson’s disease (PD) is a serious neurodegenerative condition impacting many individuals worldwide. There is a need for new non-invasive treatments of PD. Cannabinoids in the form of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) may offer utility as treatment, and our objective was hence to conduct a systematic review regarding the clinical evidence for the efficacy and safety of cannabinoids in treating PD.

Methods

Screening, data extraction, and quality assessments were all conducted by multiple reviewers, with discrepancies resolved by consensus.

Results

After conducting searches in 4 different databases, 673 articles were screened. Thirteen articles were deemed eligible for inclusion in this review. It was shown that cannabis, CBD, and nabilone (a synthetic form of THC) were capable of consistently improving motor symptoms more than a placebo. All treatments improved various non-motor symptoms, particularly with cannabis improving pain intensity, and CBD improving psychiatric symptoms in a dose-dependent manner. Adverse effects were usually minor, and, in the case of CBD, rare (except at very high doses).

Conclusion

Cannabinoids have been shown to safely offer important potential in treating motor symptoms in PD and some non-motor symptoms. More large-scale randomized control trials for specific forms of cannabinoid treatments are required to determine their overall efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabinoidsParkinson DiseaseCannabidiolCannabisDrug-Related Side Effects and Adverse ReactionsHallucinogensHumans

Stichwörter der Autor:innen

Parkinson's diseasecannabidiolcannabisclinical studiesclinical trialssymptomstetrahydrocannabinol

Substanzen

CannabinoidsCannabidiolHallucinogens

Autor:innen und Institutionen

  • School of Medicine, Deakin University, Waurn Ponds, Victoria, Australia.
  • School of Preventive and Population Health, Monash University, Melbourne, Victoria, Australia.
  • College of Dentistry, University of Illinois Chicago, Chicago, Illinois, USA.
  • Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China.

ORCID-Profile: Karan Varshney

Zitieren

APA

Varshney, K., Patel, A., Ansari, S., Shet, P., & Panag, S. S. (2023). Cannabinoids in Treating Parkinson's Disease Symptoms: A Systematic Review of Clinical Studies. Cannabis & Cannabinoid Research, 8(5), 716-730. https://doi.org/10.1089/can.2023.0023

Vancouver

Varshney K, Patel A, Ansari S, Shet P, Panag SS. Cannabinoids in Treating Parkinson's Disease Symptoms: A Systematic Review of Clinical Studies. Cannabis & Cannabinoid Research. 2023;8(5):716-730. doi:10.1089/can.2023.0023

BibTeX
@article{Varshney2023,
  author = {Varshney, Karan and Patel, Akash and Ansari, Siraaj and Shet, Pavan and Panag, Sohan Singh},
  title = {Cannabinoids in Treating Parkinson's Disease Symptoms: A Systematic Review of Clinical Studies},
  journal = {Cannabis & Cannabinoid Research},
  year = {2023},
  volume = {8},
  number = {5},
  pages = {716--730},
  doi = {10.1089/can.2023.0023}
}
Kostenlos starten →